enGene Therapeutics Inc.
ENGN Nasdaq
SEC CIK 1980845
Follow enGene Therapeutics
Weekly email: filings, results
Net income
−$32.5M
−12.1% vs same quarter last year
EPS, diluted
−$0.47
+17.5% vs same quarter last year
Operating cash flow
−$18.9M
+26.1% vs same quarter last year
Operating income
−$34M
−13.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$100.7M |
| FY24 | −$49.2M |
| FY23 | −$25.1M |
| FY22 | −$17.7M |
| FY21 | - |